

RECEIVED

JUL 02 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 078883/0120

#7
Pat. Am. B.
w/ Seq. List
5/7/01



In re patent application of
Miles William CARROLL et al.

Serial No. 09/533,798

Filed: March 24, 2000

For: POLYPEPTIDE

Group Art Unit: 1643

Examiner: Unassigned

SUPPLEMENTAL AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Supplemental to the Amendment and Reply filed March 24, 2000, please amend the above application as follows:

IN THE SPECIFICATION:

In accordance with 37 CFR §§ 1.821-1.825, kindly ~~substitute~~ for the original sequence listing the following substitute sequence listing, and please enter the corresponding amendments to the specification. The changes to the specification are shown explicitly in the attached "Version with Markings to Show Changes Made."

Kindly replace the paragraph found on page 54, line 10, with the following new paragraph:

It is possible to modify human 5T4 to enhance its immunogenicity and thus induce more efficacious immunotherapy responses. To do this, identification of HLA CTL epitopes and modification of such epitopes to improve binding to the HLA molecule, and thus more efficient CTL induction, is performed using the programme "Peptide Binding Predictions" devised by K. Parker at the National Institutes of Health; <http://www.bimas.dcrt.nih.gov/cgi-bin/molbio/ken_parker_comboform> (see Parker *et al.*, *J. Immunol.*, 152:163 (1994)). The following results are obtained for human (Table 4) and murine (Table 5) 5T4 9mers:

B
can't

Seq. list
placed
before